Когнитивные нарушения у пациентов с болезнью Паркинсона

Закрыть метаданные

Рекомендуем статьи по данной теме:

Когнитивные нарушения при посттравматическом стрессовом расстройстве. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(5):69-74

Витамины группы B и заболевания периферической нервной системы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(5):75-82

Когнитивно-поведенческая терапия при хронической мигрени и сочетанной хронической инсомнии: проспективное рандомизированное исследование. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(5-2):110-117

Особенности нарушений когнитивных функций при биполярном аффективном расстройстве. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(6):15-19

Когнитивные нарушения и эмоциональные расстройства и их коррекция у женщин в перименопаузальном периоде. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(6):48-53

Метаанализ рандомизированных контролируемых исследований эффективности препарата Проспекта в терапии сосудистых когнитивных нарушений разной степени выраженности. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(6):62-69

Проблемы организации нейрохирургической помощи пациентам с болезнью Паркинсона в Российской Федерации. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2024;(3):5-13

Коморбидные расстройства и факторы риска нейропатической боли при дистальной диабетической полинейропатии. Российский журнал боли. 2024;(2):41-48

Лечение заболеваний человека методом клизменной трансплантации фекальной микробиоты. Методические рекомендации. Профилактическая медицина. 2024;(6):79-87

Влияние предшествующей аппендэктомии на когнитивные нарушения у взрослых: исследование «случай-контроль». Хирургия. Журнал им. Н.И. Пирогова. 2024;(7):73-77

Болезнь Паркинсона (БП) проявляется как моторными, так и немоторными симптомами, среди которых важное место занимают когнитивные нарушения. В статье приводится обзор спектра когнитивных расстройств при БП, разбирается их патоморфологическая и нейротрансмиттерная основа. Обсуждаются факторы риска, критерии диагностики, вопросы комплексной терапии, включающей как нейротрансмиттерные, так и нейротрофические препараты, методы физической и когнитивной реабилитации.

Ключевые слова:

болезнь Паркинсона

когнитивные нарушения

деменция

умеренное когнитивное расстройство

патогенез

терапия

нейротрофическая терапия

Авторы:

Катунина Е.А.

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России (Пироговский университет);
ФГБУ «Федеральный центр мозга и нейротехнологий» Федерального медико-биологического агентства России

ORCID: 0000-0001-5805-486X

Парусова А.В.

ФГБУ «Федеральный центр мозга и нейротехнологий» Федерального медико-биологического агентства России

ORCID: 0009-0001-1366-766X

Голованова И.В.

ГБУЗ «Городская клиническая больница №1 имени Н.И. Пирогова Департамента здравоохранения Москвы»

ORCID: 0009-0005-8365-6113

Завадцева Н.В.

ГБУЗ «Городская клиническая больница №1 имени Н.И. Пирогова Департамента здравоохранения Москвы»

ORCID: 0009-0007-1823-2300

Дата поступления:

09.10.2024

Дата принятия в печать:

14.10.2024

Список литературы:

Katunina E, Titova N. The Epidemiology of Nonmotor Symptoms in Parkinson’s Disease (Cohort and Other Studies). International Review of Neurobiology. 2017;133:91-110. https://doi.org/10.1016/bs.irn.2017.05.012
Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2019;34(10):1464-1470. https://doi.org/10.1002/mds.27802
Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708-1713. https://doi.org/10.1212/01.wnl.0000036610.36834.e0
Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism & Related Disorders. 2011;17(4):265-269. https://doi.org/10.1016/j.parkreldis.2011.01.003
Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet. Neurology. 2012;11(8):697-707. https://doi.org/10.1016/S1474-4422(12)70152-7
Perez F, Helmer C, Foubert-Samier A, et al. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimer’s & Dementia. 2012;8(6):463-469. https://doi.org/10.1016/j.jalz.2011.09.230
Kim JW, Cheon SM, Park MJ, et al. Cognitive impairment in Parkinson’s disease without dementia: subtypes and influences of age. Journal of Clinical Neurology. 2009;5(3):133-138. https://doi.org/10.3988/jcn.2009.5.3.133
Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). Journal of Neurology. 2008;255(2):255-264. https://doi.org/10.1007/s00415-008-0720-2
Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement Disorders. 2005;20(10):1255-1263. https://doi.org/10.1002/mds.20527
Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(11):2958-2969. https://doi.org/10.1093/brain/awp245
Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84(11):1258-1264. https://doi.org/10.1136/jnnp-2013-305277
Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837-844. https://doi.org/10.1002/mds.21956
Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9(1):63-75. https://doi.org/10.1016/j.jalz.2012.11.007
Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062-1069. https://doi.org/10.1212/WNL.0b013e3181f39d0e
Broeders M, de Bie RM, Velseboer DC, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81(4):346-352. https://doi.org/10.1212/WNL.0b013e31829c5c86
Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. Neurology. 2017;88(8):767-774. https://doi.org/10.1212/WNL.0000000000003634
Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: A meta-analysis. Movement Disorders. 2020;35(1):45-54. https://doi.org/10.1002/mds.27902
Lawson RA, Yarnall AJ, Duncan GW, et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2017;88(8):648-652. https://doi.org/10.1136/jnnp-2016-315099
Domellöf ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurologica Scandinavica. 2015;132(2):79-88. https://doi.org/10.1111/ane.12375
Roberts R, Knopman DS. Classification and epidemiology of MCI.. Clinics in Geriatric Medicine. 2013;29(4):753-772. https://doi.org/10.1016/j.cger.2013.07.003
Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. Journal of the American Geriatrics Society. 2000;48(8):938-942. https://doi.org/10.1111/j.1532-5415.2000.tb06891.x
Schrag A, Siddiqui UF, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet. Neurology. 2017;16(1):66-75. https://doi.org/10.1016/S1474-4422(16)30328-3
Jones JD, Kuhn TP, Szymkowicz SM. Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: Analysis of the PPMI cohort. Parkinsonism & Related Disorders. 2018;47:3-7. https://doi.org/10.1016/j.parkreldis.2017.12.006
Skorvanek M, Goldman JG, Jahanshahi M, et al. Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations. Movement Disorders. 2018;33(2):208-218. https://doi.org/10.1002/mds.27233
Matteau E, Dupré N, Langlois M, et al. Mattis Dementia Rating Scale 2: screening for MCI and dementia. American Journal of Alzheimer’s Disease and Other Dementias. 2011;26(5):389-398. https://doi.org/10.1177/1533317511412046
Matteau E, Dupré N, Langlois M, et al. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. Journal of Geriatric Psychiatry and Neurology. 2012;25(2):100-106. https://doi.org/10.1177/0891988712445086
Bezdicek O, Michalec J, Nikolai T, et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson’s disease and normative data. Dementia and Geriatric Cognitive Disorders. 2015;39(5-6):303-311. https://doi.org/10.1159/000375365
Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717-1725. https://doi.org/10.1212/WNL.0b013e3181fc29c9
Lucza T, Karádi K, Kállai J, et al. Screening Mild and Major Neurocognitive Disorders in Parkinson’s Disease. Behavioural neurology. 2015;2015:983606. https://doi.org/10.1155/2015/983606
Bezdicek O, Majerova V, Novak M, et al. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington’s disease. Applied neuropsychology. Adult. 2013;20(1):33-40. https://doi.org/10.1080/09084282.2012.670158
Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Movement Disorders. 2008;23(7):998-1005. https://doi.org/10.1002/mds.22007
Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, et al. Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Movement Disorders. 2013;28(10):1376-1383. https://doi.org/10.1002/mds.25568
Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Movement Disorders. 2012;27(3):349-356. https://doi.org/10.1002/mds.24893
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders. 2007;22(12):1689-1707. https://doi.org/10.1002/mds.21507
Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral sciences. 2021;11(5):74. https://doi.org/10.3390/bs11050074
Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers. 2021;7(1):47. https://doi.org/10.1038/s41572-021-00280-3
Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Movement Disorders. 2018;33(12):1857-1870. https://doi.org/10.1002/mds.27527
Kasten M, Klein C. The many faces of alpha-synuclein mutations. Movement Disorders. 2013;28(6):697-701. https://doi.org/10.1002/mds.25499
Zhang Y, Sun QY, Zhao YW, et al. Effect of GBA Mutations on Phenotype of Parkinson’s Disease: A Study on Chinese Population and a Meta-Analysis. Parkinson’s disease. 2015;2015:916971. https://doi.org/10.1155/2015/916971
Creese B, Bell E, Johar I, et al. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and Lewy body dementias: Review and meta-analyses. American Journal of Medical Genetics. 2018;177(2):232-241. https://doi.org/10.1002/ajmg.b.32549
Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Annals of Neurology. 2016;80(5):674-685. https://doi.org/10.1002/ana.24781
Piredda R, Desmarais P, Masellis M, Gasca-Salas C. Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review. European Journal of Neurology. 2020;27(2):229-234. https://doi.org/10.1111/ene.14115
Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson’s Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Movement Disorders. 2018;33(5):730-741. https://doi.org/10.1002/mds.27352
Grünewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurology. 2013;70(9):1186-1191. https://doi.org/10.1001/jamaneurol.2013.488
Liu R, Umbach DM, Peddada SD, et al. Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. Neurology. 2015;84(21):2107-2115. https://doi.org/10.1212/WNL.0000000000001609
Munro CA, Winicki JM, Schretlen DJ, et al. Sex differences in cognition in healthy elderly individuals. Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition. 2012;19(6):759-768. https://doi.org/10.1080/13825585.2012.690366
Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism and Related Disorders. 2014;20(1):99-105. https://doi.org/10.1016/j.parkreldis.2013.09.025
Guo Y, Xu W, Liu FT, et al. Modifiable risk factors for cognitive impairment in Parkinson’s disease: A systematic review and meta-analysis of prospective cohort studies. Movement Disorders. 2019;34(6):876-883. https://doi.org/10.1002/mds.27665
Nicoletti A, Luca A, Baschi R, et al. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study. Journal of Neurology. 2021;268(2):549-558. https://doi.org/10.1007/s00415-020-10189-8
Ashraghi MR, Pagano G, Polychronis S, et al. Parkinson’s Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery. 2016;10(1):11-21. https://doi.org/10.2174/1872214810999160628105549
Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology. 2000;54(10):1916-1921. https://doi.org/10.1212/wnl.54.10.1916
Chahine LM, Dos Santos C, Fullard M, et al. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson’s disease. European Journal of Neurology. 2019;26(2):246-e18. https://doi.org/10.1111/ene.13797
Erten-Lyons D, Woltjer R, Kaye J, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology. 2013;81(11):977-983. https://doi.org/10.1212/WNL.0b013e3182a43e45
Козак В.В. Определение риска деменции при болезни Паркинсона: возможности и перспективы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(6):137-143. https://doi.org/10.17116/jnevro2019119061137
David FJ, Robichaud JA, Leurgans SE, et al. Exercise improves cognition in Parkinson’s disease: The PRET-PD randomized, clinical trial. Movement Disorders. 2015;30(12):1657-1663. https://doi.org/10.1002/mds.26291
Picelli A, Varalta V, Melotti C, et al. Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson’s disease: a pilot, single-blind, randomizedtrial. Functional Neurology. 2016;31(1):25-31. https://doi.org/10.11138/fneur/2016.31.1.025
Cho BH, Choi SM, Kim JT, Kim BC. Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson’s disease. Parkinsonism and Related Disorders. 2018;50:42-47. https://doi.org/10.1016/j.parkreldis.2018.02.016
Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? Journal of Geriatric Psychiatry and Neurology. 2014;27(4):276-281. https://doi.org/10.1177/0891988714532015
Galtier I, Nieto A, Lorenzo JN, Barroso J. Subjective cognitive decline and progression to dementia in Parkinson’s disease: a long-term follow-up study. Journal of Neurology. 2019;266(3):745-754. https://doi.org/10.1007/s00415-019-09197-0
Клинические рекомендации. Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. 2021. Ссылка активна на 26.09.24. https://disuria.ru/_ld/12/1253_kr21G20G23MZ.pdf
Sasikumar S, Strafella AP. Imaging Mild Cognitive Impairment and Dementia in Parkinson’s Disease. Frontiers in Neurology. 2020;11:47. https://doi.org/10.3389/fneur.2020.00047
Westbrook A, van den Bosch R, Määttä JI, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020;367(6484):1362-1366. https://doi.org/10.1126/science.aaz5891
Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research. 2004;318(1):121-134. https://doi.org/10.1007/s00441-004-0956-9
Titova N, Qamar MA, Chaudhuri KR. Biomarkers of Parkinson’s Disease: An Introduction. International review of Neurobiology. 2017;132:183-196. https://doi.org/10.1016/bs.irn.2017.03.003
Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Annals of Clinical and Translational Neurology. 2015;2(10):949-959. https://doi.org/10.1002/acn3.246
Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016;91(6):1199-1218. https://doi.org/10.1016/j.neuron.2016.09.006
Bohnen NI, Albin RL, Müller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurology. 2015;72(2):194-200. https://doi.org/10.1001/jamaneurol.2014.2757
Pereira JB, Hall S, Jalakas M, et al. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease. Neurobiology of Disease. 2020;139:104831. https://doi.org/10.1016/j.nbd.2020.104831
Smith C, Malek N, Grosset K, et al. Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies. Journal of Neurology, Neurosurgery, and Psychiatry. 2019;90(11):1234-1243. https://doi.org/10.1136/jnnp-2019-321111
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14(4):535-562. https://doi.org/10.1016/j.jalz.2018.02.018
Winer JR, Maass A, Pressman P, et al. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease. JAMA Neurology. 2018;75(2):227-235. https://doi.org/10.1001/jamaneurol.2017.3713
Reimand J, Collij L, Scheltens P, et al; Alzheimer’s Disease Neuroimaging Initiative. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 2020;95(19):e2648-e2657. https://doi.org/10.1212/WNL.0000000000010739
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. New England Journal of Medicine, NEJM. 2004;351(24):2509-2518. https://doi.org/10.1056/NEJMoa041470
Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Movement Disorders. 2015;30(7):912-918. https://doi.org/10.1002/mds.26236
Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Movement Disorders. 2012;27(10):1230-1238. https://doi.org/10.1002/mds.25098
Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Movement Disorders. 2019;34(2):180-198. https://doi.org/10.1002/mds.27602
Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet. Neurology. 2009;8(7):613-618. https://doi.org/10.1016/S1474-4422(09)70146-2
Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet. Neurology. 2010;9(10):969-977. https://doi.org/10.1016/S1474-4422(10)70194-0
Stubendorff K, Larsson V, Ballard C, et al. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158. https://doi.org/10.1136/bmjopen-2014-005158
Gauthier S, Proaño JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders. 2015;39(5-6):332-347. https://doi.org/10.1159/000377672
Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2019;2019(11):CD008900. https://doi.org/10.1002/14651858.CD008900.pub3
Alvarez XA, Alvarez I, Iglesias O, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. International Journal of Neuropsychopharmacology. 2016;19(6):pyw024. https://doi.org/10.1093/ijnp/pyw024
Дамулин И.В., Мхитарян Э.А., Коберская Н.Н. Церебролизин для лечения легких когнитивных нарушений сосудистого генеза. Терапевтический архив. 2007;79(6):65-69.
Мищенко В.Н. К вопросу об эффективности препарата Церебролизин у больных с «немыми» инфарктами мозга. Международный неврологический журнал. 2015;3(73):15-20.
Castrén E, Võikar V, Rantamäki T. Role of neurotrophic factors in depression. Current Opinion in Pharmacology. 2007;7(1):18-21. https://doi.org/10.1016/j.coph.2006.08.009
Зуйкова Н.Л., Исраелян А.Ю., Гушанская Е.В., Медведев В.Э. Церебролизин в терапии депрессий. Психиатрия и психофармакотерапия. 2013;1:41-46.
Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology. 2011;18(1):59-68. https://doi.org/10.1111/j.1468-1331.2010.03092.x
Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Current Alzheimer Research. 2011;8(5):583-591. https://doi.org/10.2174/156720511796391863
Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. https://doi.org/10.1161/STROKEAHA.115.009416
Левин О.С., Вознюк И.А., Иллариошкин С.Н. и др. Когнитивные нарушения и тактика применения препарата Церебролизин. Резолюция международного совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(9):121-130. https://doi.org/10.17116/jnevro2023123091121
Lawrence BJ, Gasson N, Bucks RS, et al. Cognitive Training and Noninvasive Brain Stimulation for Cognition in Parkinson’s Disease: A Meta-analysis. Neurorehabilitation and Neural Repair. 2017;31(7):597-608. https://doi.org/10.1177/1545968317712468
Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database of Systematic Reviews. 2020;2(2):CD011961. https://doi.org/10.1002/14651858.CD011961.pub2
da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113. https://doi.org/10.1371/journal.pone.0193113
Dinkelbach L, Brambilla M, Manenti R, Brem AK. Non-invasive brain stimulation in Parkinson’s disease: Exploiting crossroads of cognition and mood. Neurosci Biobehavioral Reviews. 2017;75:407-418. https://doi.org/10.1016/j.neubiorev.2017.01.021
Package of interventions for rehabilitation. Module 3. Neurological conditions. Geneva: World Health Organization; 2023. Accessed September 26, 2024. https://www.who.int/publications/i/item/9789240071131

Закрыть метаданные